Ironwood Pharmaceuticals, Inc. Class A (IRWD)

In the past six months, Ironwood Pharmaceuticals' stock has experienced significant movement, with the share price at $3.51 as of April 8, 2026, a 240.78% increase compared to April 9, 2025. Key events include the Q4 and Full Year 2025 Earnings Report, which caused a stock decline despite LINZESS demand growth, the 2026 Financial Guidance projecting LINZESS U.S. net sales of $1.125 to $1.175 billion, the finalization of the confirmatory Phase 3 clinical trial design for apraglutide in SBS-IF, and insider selling amounting to $20,528,940.00.

Specific, publicly available data on the demand seasonality for Ironwood Pharmaceuticals' products and services is not detailed. The company's primary product, LINZESS, addresses chronic conditions like IBS-C and CIC, which typically do not exhibit strong seasonal demand fluctuations.

Ironwood Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on therapies for gastrointestinal (GI) and rare diseases. Their flagship product is linaclotide, marketed as LINZESS in the United States and CONSTELLA in select ex-U.S. markets, indicated for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), and for pediatric patients aged 6-17 years with functional constipation. The company is also advancing apraglutide for rare gastrointestinal diseases and IW-3300 for visceral pain conditions, and CNP-104 for primary biliary cholangitis (PBC).

Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with additional operations in Basel, Switzerland. They co-develop and co-commercialize LINZESS with AbbVie Inc. in the United States, where AbbVie also markets it as CONSTELLA in Europe. Astellas Pharma Inc. is their partner for marketing LINZESS in Japan. Furthermore, Ironwood has partnerships with AstraZeneca AB for development and commercialization in China, and with AbbVie for other territories worldwide.

Information specifically detailing Ironwood Pharmaceuticals' brand reputation in the past year or events that have explicitly affected it is not readily available. The company is generally described as a "leading GI healthcare company" and a "pioneer in the development of LINZESS." LINZESS is noted as the #1 prescribed brand in the U.S. for IBS-C and CIC.

Ironwood Pharmaceuticals has a mixed ownership structure, with institutional investors holding approximately 25.10% to 94.83% of the stock, insiders holding around 9.36% to 36.16%, and retail investors holding approximately 32.95%. Major institutional owners include Armistice Capital, Llc, Vanguard Group Inc, Sarissa Capital Management LP, and BlackRock, Inc. Notable individual owners include Alexander Denner and Bryan E. Roberts, with Bryan E. Roberts being the largest individual shareholder.